Video

Cost Containment's Impact on Oncology Practices

Documentation associated with prior authorization and other cost-containment efforts places an administrative burden on oncologists, according to Jeffrey C. Ward, MD, who notes that he personally spends approximately 2 hours each day on such documentation. The result, he says, is less time for patient care.

Much of the burden is due to Medicare, not commercial payer requirements, since Medicare has a very complex claims-payment system, says Michael Kolodziej, MD. Both Medicare and commercial payers fall short in understanding what oncologists do, and thus apply sets of rules across the spectrum of healthcare that are not easily implemented in oncology, notes Kolodziej.

Prior authorization, which is designed to mitigate risk, is costly to both the oncology practice and the payer. There is still a need for oncologists to document that they are practicing evidence-based treatment, notes Kolodziej. However, this need will lessen as providers take on more risk. It is important that oncologists are held accountable for what they can control, not for what they cannot control, remarks Ward.

Payment reform efforts in oncology are designed to incentivize value-based care. Oncologists, who need to have some flexibility in their care decisions, often struggle with thinking in terms of value, notes Ward.

Related Videos
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.